| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
1-Stearoyl-sn-glycero-3-phosphocholine targets lipid metabolism pathways and cell membranes. As a lysophosphatidylcholine, it is involved in lipid signaling, membrane structure, and inflammation. It is a substrate for enzymes such as lysophospholipase and acyltransferase. Its "target" in research is the study of lipid metabolism and signaling.
|
|---|---|
| ln Vitro |
In vitro, 1-Stearoyl-sn-glycero-3-phosphocholine is used to study lipid metabolism, cell signaling, and inflammation. It can activate various signaling pathways and modulate immune cell function. Its activity is measured by assessing its effects on cell proliferation, cytokine production, and lipid mediator generation in cultured cells.
|
| ln Vivo |
In vivo, 1-Stearoyl-sn-glycero-3-phosphocholine is a naturally occurring lysophospholipid involved in lipid metabolism and signaling. It is present in plasma and tissues and plays a role in inflammation and atherosclerosis. Its levels may be altered in metabolic diseases and inflammatory conditions.
|
| Enzyme Assay |
In vitro enzyme assays with 1-Stearoyl-sn-glycero-3-phosphocholine typically involve studying lysophospholipase, acyltransferase, or phospholipase A2. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating with enzyme preparations and measuring the release of fatty acids or lysophosphatidylcholine products by chromatographic methods.
|
| Cell Assay |
In vitro cell culture experiments with 1-Stearoyl-sn-glycero-3-phosphocholine involve treating various cell types including endothelial cells, macrophages, and smooth muscle cells. Cells are treated with the compound, and endpoints include assessment of cell proliferation, inflammation (cytokine production), apoptosis, and signaling pathway activation. These experiments characterize the biological effects of lysophosphatidylcholine.
|
| Animal Protocol |
In vivo animal experiments with 1-Stearoyl-sn-glycero-3-phosphocholine typically involve administering the compound to animal models of atherosclerosis, inflammation, or metabolic disease. Key endpoints include assessment of plasma lipid levels, inflammatory markers, and histopathological examination of tissues. These studies investigate the role of lysophosphatidylcholine in disease pathogenesis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 1-Stearoyl-sn-glycero-3-phosphocholine reflect its role as a lipid metabolite. It is present in plasma lipoproteins and is rapidly metabolized by lysophospholipase and other enzymes. Its levels in plasma reflect lipid metabolism and may be altered in disease states. It should be stored frozen at -20°C.
|
| Toxicity/Toxicokinetics |
1-Stearoyl-sn-glycero-3-phosphocholine has a low toxicity profile as a naturally occurring lipid metabolite. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have not been published for this compound. It has a purity of >98.0%.
|
| Additional Infomation |
1-Stearyl-sn-glycerol-3-phosphate choline is a lysophosphatidylcholine 18:0 with its acyl substituent at the 1-position and specifically designated as stearoyl. It is a mouse metabolite and an inducer of apoptosis. It is a 1-O-acyl-sn-glycerol-3-phosphate choline, also a lysophosphatidylcholine 18:0. Functionally, it is associated with octadecanoic acid. 1-O-acyl-sn-glycerol-3-phosphate choline has been reported in Homo sapiens, Blephalosporinus japonicus, and other organisms with relevant data. PC (18:0/0:0) is a metabolite found or produced in Saccharomyces cerevisiae.
1-Stearoyl-sn-glycero-3-phosphocholine (18:0 Lyso-PC) is a saturated lysophosphatidylcholine consisting of a stearoyl acyl chain. It is a product of lipid metabolism and is used in lipid metabolism studies. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C26H54NO7P
|
|---|---|
| Molecular Weight |
523.68
|
| Exact Mass |
523.363
|
| CAS # |
19420-57-6
|
| Related CAS # |
1-Stearoyl-sn-glycero-3-phosphocholine-d35;327178-92-7
|
| PubChem CID |
497299
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
35
|
| Complexity |
546
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
|
| InChi Key |
IHNKQIMGVNPMTC-RUZDIDTESA-N
|
| InChi Code |
InChI=1S/C26H54NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26(29)32-23-25(28)24-34-35(30,31)33-22-21-27(2,3)4/h25,28H,5-24H2,1-4H3/t25-/m1/s1
|
| Chemical Name |
[(2R)-2-hydroxy-3-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9096 mL | 9.5478 mL | 19.0956 mL | |
| 5 mM | 0.3819 mL | 1.9096 mL | 3.8191 mL | |
| 10 mM | 0.1910 mL | 0.9548 mL | 1.9096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
